Less than 2 weeks to abstract release
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
-
biopearl123
- Posts: 2591
- Joined: Fri Jul 20, 2018 5:13 pm
Less than 2 weeks to abstract release
And we apparently (abruptly) have lost our (?former) Chief Medical Officer. So far with no announcement or indication of direction. Shameful Geron (lack of) IR. With ASH approaching this is one less voice to represent the company, doctor to doctor, oncologist to oncologist. Dr. Eid has not been as visible as Faye but may be up to the job. Am hoping Faye’s departure is not a statement of no confidence in company or the company’s vote of no confidence in her. Doubt the latter, but studies large and small going on that were previously under her guidance and she masterfully steered the company through the FDA’s harsh review. Silence on the part of Geron is poor form. Coincidence that Dawn added another board position to her plate?
-
huntingonthebluffs
- Posts: 338
- Joined: Wed Feb 24, 2016 12:00 am
Re: Less than 2 weeks to abstract release
Yes absolutely spot on regarding Dr Faye Feller, Geron’s CMO (apparently former) IMO. I thought she was perfect for the job, based resume, per her statements regarding her career goals and path, and of course navigating the FDA hostilities, CT activity, etc. Since nothing has been announced I assume there is possibility a high stakes chess match going on in some way. Is it too much too hope she is away on temporary leave or efforts are being made to resolve whatever happened.
Re: Less than 2 weeks to abstract release
Don’t blame me blame ChatGPT:::
If you get all the way to the bottom you’ll see what BioPearl pointed out, that an 8-K will need to be filed….
Excellent question — and yes, the same phenomenon absolutely occurs with Chief Medical Officers (CMOs) at public biotech and pharmaceutical companies, though the reasons and implications are a bit different from a marketing context.
Here’s a focused breakdown for Chief Medical Officers (biotech/pharma):
⸻
1. Pre-Takeover CMO Departures Are Common in Biotech
In biotech, the Chief Medical Officer is a key strategic executive, often responsible for clinical development, regulatory interactions (FDA, EMA, etc.), and medical strategy.
Departures before takeovers can occur because:
• Clinical program completion: Once pivotal trials end, the CMO’s primary work may be done — making their departure natural as a deal approaches.
• Strategic misalignment: The incoming acquirer may have different priorities (e.g., combining pipelines, cutting duplicative roles).
• Insider knowledge and timing: CMOs are often among the first to know a deal is being explored and may choose to leave before changes are public or before insider trading restrictions tighten.
• Retention planning: Acquirers sometimes negotiate retention packages for only select executives (e.g., CEO, CFO) — leading others like the CMO to depart preemptively.
⸻
2. Notable Real-World Examples
Here are a few real or recent patterns seen in public biotech companies:
• ImmunoGen (2023): The CMO left shortly before AbbVie announced its $10B acquisition — analysts noted it likely reflected the company preparing for integration.
• Mirati Therapeutics (2023): CMO Charles Baum left months before Bristol Myers Squibb’s $5.8B acquisition; his exit was seen as part of Mirati’s pre-deal restructuring.
• Five Prime Therapeutics (2021): The CMO transitioned out just before Amgen’s $1.9B acquisition — common when a company’s lead asset has completed pivotal trials and is transitioning to commercial hands.
• Receptos (2015): CMO Shehnaaz Suliman’s move preceded Celgene’s $7.2B acquisition; she later joined a new biotech startup — a classic case of execs exiting pre-takeover.
⸻
3. How Investors Interpret These Exits
When a biotech CMO departs suddenly, investors often read it through one of these lenses:
• Positive or neutral: The lead drug is “de-risked,” and the company is transitioning to M&A or commercial mode.
• Negative: If it happens mid-trial or without clear succession, it can suggest internal friction or data concerns.
• Speculative: Biotech investors sometimes view unexpected CMO resignations as a “tell” for an upcoming strategic transaction (M&A, partnership, or licensing).
⸻
4. Disclosure & Compliance
Because CMOs are almost always named executive officers in public biotechs, their departures must be disclosed in Form 8-K filings (Item 5.02).
Analysts and biotech investors routinely scan these filings for early M&A signals — especially if a departure coincides with:
• NDA or BLA submission milestones,
• Phase 3 completion, or
• Quiet periods before major conferences (e.g., ASCO, AACR, JPM).
If you get all the way to the bottom you’ll see what BioPearl pointed out, that an 8-K will need to be filed….
Excellent question — and yes, the same phenomenon absolutely occurs with Chief Medical Officers (CMOs) at public biotech and pharmaceutical companies, though the reasons and implications are a bit different from a marketing context.
Here’s a focused breakdown for Chief Medical Officers (biotech/pharma):
⸻
1. Pre-Takeover CMO Departures Are Common in BiotechIn biotech, the Chief Medical Officer is a key strategic executive, often responsible for clinical development, regulatory interactions (FDA, EMA, etc.), and medical strategy.
Departures before takeovers can occur because:
• Clinical program completion: Once pivotal trials end, the CMO’s primary work may be done — making their departure natural as a deal approaches.
• Strategic misalignment: The incoming acquirer may have different priorities (e.g., combining pipelines, cutting duplicative roles).
• Insider knowledge and timing: CMOs are often among the first to know a deal is being explored and may choose to leave before changes are public or before insider trading restrictions tighten.
• Retention planning: Acquirers sometimes negotiate retention packages for only select executives (e.g., CEO, CFO) — leading others like the CMO to depart preemptively.
⸻
2. Notable Real-World ExamplesHere are a few real or recent patterns seen in public biotech companies:
• ImmunoGen (2023): The CMO left shortly before AbbVie announced its $10B acquisition — analysts noted it likely reflected the company preparing for integration.
• Mirati Therapeutics (2023): CMO Charles Baum left months before Bristol Myers Squibb’s $5.8B acquisition; his exit was seen as part of Mirati’s pre-deal restructuring.
• Five Prime Therapeutics (2021): The CMO transitioned out just before Amgen’s $1.9B acquisition — common when a company’s lead asset has completed pivotal trials and is transitioning to commercial hands.
• Receptos (2015): CMO Shehnaaz Suliman’s move preceded Celgene’s $7.2B acquisition; she later joined a new biotech startup — a classic case of execs exiting pre-takeover.
⸻
3. How Investors Interpret These ExitsWhen a biotech CMO departs suddenly, investors often read it through one of these lenses:
• Positive or neutral: The lead drug is “de-risked,” and the company is transitioning to M&A or commercial mode.
• Negative: If it happens mid-trial or without clear succession, it can suggest internal friction or data concerns.
• Speculative: Biotech investors sometimes view unexpected CMO resignations as a “tell” for an upcoming strategic transaction (M&A, partnership, or licensing).
⸻
4. Disclosure & ComplianceBecause CMOs are almost always named executive officers in public biotechs, their departures must be disclosed in Form 8-K filings (Item 5.02).
Analysts and biotech investors routinely scan these filings for early M&A signals — especially if a departure coincides with:
• NDA or BLA submission milestones,
• Phase 3 completion, or
• Quiet periods before major conferences (e.g., ASCO, AACR, JPM).